To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2).
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) / Bauckneht, M., Rebuzzi, S.E., Signori, A., Frantellizzi, V., Murianni, V., Lodi Rizzini, E., Mascia, M., Lavelli, V., Donegani, M.I., Ponzano, M., Gaudiano, A., Stazza, M.L., Licari, M., Cavallini, L., Laghi, V., Cindolo, L., Maggi, M., Sciarra, A., Mammucci, P., Sambuceti, G., et al.. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - (2022). [10.1007/s00259-021-05550-6]
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
Stazza, Maria Lina;Spanu, Angela;
2022-01-01
Abstract
To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2).| File | Dimensione | Formato | |
|---|---|---|---|
|
Bauckneht2021_Article_ThePrognosticPowerOfInflammato.pdf
accesso aperto
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Creative commons
Dimensione
1.44 MB
Formato
Adobe PDF
|
1.44 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
